EverTree Bio

Name

EverTree Bio

Legal name

EverTree Bio

Website

https://evertreebio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

AI-Driven Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI drug discovery
• Stem cell biology
• Virtual human modeling
• Neurodegenerative therapeutics
• Small molecule discovery

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Discovery Partnerships and Licensing: EverTree Bio generates revenue through strategic partnerships with pharmaceutical and biotech companies for drug discovery services, platform access, and potentially co-development agreements for their pipeline programs. As a clinical-stage biotech with lead programs in CMT1A, ALS, and Alzheimer's, the company likely pursues a combination of upfront payments, milestone payments, and royalties from partnered drug candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

EverTree Bio operates an AI-driven drug discovery platform that combines proprietary AI models (TREE Model) with human pluripotent stem cell (hPSC)-derived cell types to deliver end-to-end drug development applications including target discovery, hit optimization, efficacy predictions, and toxicity predictions. The company also develops its own therapeutic pipeline led by a CMT1A small molecule program, with additional ALS and Alzheimer's programs.

Product overview

EverTree Bio operates as a unified AI-driven drug discovery platform comprising the TREE Model (Tissue Response Expert Ensemble) for predictive analytics in target discovery and hit optimization, and BioCodex v1 containing 2 trillion tokens of cell-gene-drug interaction data. The platform is powered by patented hPSC-derived cell type technology that generates human cell types at scale for high throughput data generation. Therapeutic applications include target discovery, hit discovery and optimization, efficacy predictions (on-target and off-target), and biomarker predictions. The company's pipeline includes CMT1A (lead program), ALS, and Alzheimer's programs.

Differentiator

Problem solved

Functional benefit

Products and services

• TREE Model Predictive AI platform (Tissue Response Expert Ensemble) for end-to-end drug development applications including target discovery and hit optimization, employing a mixture-of-experts architecture across diverse cell types. Sold/licensed to pharmaceutical and biotech companies for drug discovery collaborations.
• BioCodex v1 Large-scale proprietary data platform containing 2 trillion tokens of cell-gene-drug interactions generated from a mechanistically resolved drug library across diverse cell types. Used to train AI models and support drug discovery applications for pharmaceutical and biotech partners.
• hPSC-Derived Cell Types Patented platform technology that generates human cell types from induced pluripotent stem cells (iPSCs) at scale for high-throughput data generation, covering neuronal, cardiac, and gastrointestinal cell types. Underpins the company's proprietary drug discovery capabilities.
• CMT1A Program Lead small molecule therapeutic program for Charcot-Marie-Tooth Disease Type 1A (CMT1A), a debilitating progressive neurodegenerative disease caused by defective myelin. Identified as the first AI-predicted drug proven effective in vivo ($7-21B market opportunity with zero FDA-approved treatments).
• ALS Program Therapeutic program targeting Amyotrophic Lateral Sclerosis (ALS) currently in preclinical development, leveraging the company's AI-driven drug discovery platform.
• Alzheimer's Program Therapeutic program targeting Alzheimer's disease currently in preclinical development, leveraging the company's AI-driven drug discovery platform and hPSC-derived cell types.

Quantifiable outcome

• First AI-predicted drug proven effective in vivo for CMT1A
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Lantern Pharma: Clinical-stage oncology biotech using an AI platform (RADR) to identify and develop targeted therapeutics. Comparable as a smaller AI-platform biotech with both internal pipeline and partnership revenue model in pharma.
• Sangamo Therapeutics: Clinical-stage genomic medicine company using cell-based and in vivo genomic engineering to develop CNS and rare disease therapeutics. Comparable as a smaller biotech operating in the same neurodegenerative/rare-disease space with platform technology.

Direct peers

• Atomwise: AI-driven small molecule drug design company using structure-based deep learning to discover novel therapeutics across multiple disease areas. Comparable as a specialized AI drug discovery platform peer pursuing partnership-led GTM.
• Insitro: AI/ML-native drug discovery company combining machine learning with induced pluripotent stem cell-derived biology to build predictive models of disease. Closely aligned with EverTree's hPSC + AI architecture and pipeline focus.
• Schrödinger: Computational drug discovery company combining physics-based simulation with machine learning for hit identification and lead optimization. A relevant peer given EverTree's AI-driven approach to hit discovery and optimization across novel chemistry.
• Exscientia: AI-driven pharma company using end-to-end AI platforms to design and develop novel small-molecule therapeutics. Comparable as a platform-led AI drug discovery peer pursuing internal pipeline plus pharma partnerships.
• BenevolentAI: AI-driven drug discovery company combining biomedical knowledge graphs with machine learning to identify new targets and therapeutics, with a historical focus on neurodegenerative and rare diseases overlapping EverTree's pipeline.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Directly comparable as a platform-led AI biotech pursuing both internal pipeline and pharma partnerships in indications EverTree also targets.

Broad incumbents

• Ionis Pharmaceuticals: Established RNA-targeted therapeutics company with multiple approved drugs and a deep CNS/neurodegenerative pipeline. Comparable as an incumbent pursuing novel modality therapies in the same indication space EverTree targets.
• Biogen: Large pharmaceutical company specializing in neurological and neurodegenerative diseases including ALS and Alzheimer's. Represents the dominant incumbent acquirer/partner profile in EverTree's lead indication areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/evertree-bio

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EverTree Bio